Abstract Search

ba0003OP11 | Clinical | ECTS2014

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Wooddell Margaret , Kawakami Tetsuyoshi , Ito Takahiro , Zhang Xiaoping , Humphrey Jeffrey , Insogna Karl , Peacock Munro

see PP90....

0 shares

ba0003OP12 | Clinical | ECTS2014

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

Zhang Xiaoping , Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Kawakami Tetsuyoshi , Ito Takahiro , Humphrey Jeffrey , Insogna Karl , Peacock Munro

see PP91....

0 shares

ba0003pp90 | Bone development/growth and fracture repair | ECTS2014

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Wooddell Margaret , Kawakami Tetsuyoshi , Ito Takahiro , Zhang Xiaoping , Humphrey Jeffrey , Insogna Karl , Peacock Munro

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) levels. We report safety, tolerability and biochemistry markers following single ascending dose administration of KRN23 in adults with XLH.Methods: 38 XLH subjects with baseline FGF23≥30 pg/ml were randomized to receive single doses of KRN23 (K) or placebo (P) either (0.003&#15...

0 shares

ba0003pp91 | Bone development/growth and fracture repair | ECTS2014

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

Zhang Xiaoping , Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Kawakami Tetsuyoshi , Ito Takahiro , Humphrey Jeffrey , Insogna Karl , Peacock Munro

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 125-dihydroxyvitamin D (125(OH)2D) levels. We report PK and PD of KRN23 following single ascending dose administration in adults with XLH.Methods: 38 XLH patients with baseline FGF23≥30 pg/ml were randomized to receive a single dose of KRN23 (K) or placebo (P) either i.v. (0.0030.3 mg/kg) or s.c. (0.11...

0 shares

Bone Abstracts

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

BiosciAbstracts